Evaluation of a DNA demethylating agent in combination with all-trans retinoic acid for IDH1-mutant gliomas
Open Access
- 26 November 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 24 (5) , 711-723
Abstract
Isocitrate Dehydrogenase 1/2 (IDH1/2) mutations are diagnostic for Astrocytoma or Oligodendroglioma, IDH-mutant. In these IDH-mutant gliomas, retinoic acid-related gene expression is commonly silenced by DNA hypermethylation. DNA demethylating agents can epigenetically reprogram IDH-mutant cells and reduce proliferation, likely by re-expression of silenced tumor suppressor pathways. We hypothesized that DNA demethylation might restore the retinoic acid pathway and slow tumor growth. This was the rationale for a preclinical evaluation combining the DNA demethylating agent, 5-Azacytidine (5-Aza), and retinoic acid pathway activation with all-trans retinoic acid (atRA) in IDH-mutant glioma. In this study, we evaluated the effect of 5-Aza and atRA combination on cell proliferation, apoptosis, and gene expression in human glioma cells. In addition, the efficacy of this combination was tested in patient-derived xenograft (PDX) bearing the IDH1R132H mutation, utilizing subcutaneous and orthotopic models. 5-Aza reduced the DNA methylation profile and increased the gene expression of retinoic acid-related genes. Combination of 5-Aza and atRA reduced cell growth, increased differentiation marker expression, and apoptosis in IDH1R132H glioma cells. Mechanistically, 5-Aza sensitized IDHIR132H glioma cells to atRA via upregulation of the retinoic acid pathway. Importantly, the drug combination reduced significantly the growth rate of subcutaneous tumors, but in an orthotopic mouse model, the combination did not improve survival and 5-Aza alone provided the best survival benefit. Use of DNA demethylating agent in combination with retinoids shows promise, but further optimization and preclinical studies are required for treatment of intracranial IDH-mutant gliomas.Keywords
Funding Information
- National Institutes of Health (R01 CA190223)
This publication has 37 references indexed in Scilit:
- A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylationGenome Research, 2012
- Transient Low Doses of DNA-Demethylating Agents Exert Durable Antitumor Effects on Hematological and Epithelial Tumor CellsCancer Cell, 2012
- IDH mutation impairs histone demethylation and results in a block to cell differentiationNature, 2012
- Regulation of glioblastoma stem cells by retinoic acid: role for Notch pathway inhibitionOncogene, 2011
- DNA Methylation, Isocitrate Dehydrogenase Mutation, and Survival in GliomaJNCI: Journal of the National Cancer Institute, 2011
- Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of GliomaCancer Cell, 2010
- Evaluation of retinoic acid therapy for OTX2-positive medulloblastomasNeuro-Oncology, 2010
- IDH1andIDH2Mutations in GliomasNew England Journal of Medicine, 2009
- An Integrated Genomic Analysis of Human Glioblastoma MultiformeScience, 2008
- Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cellsNature, 2006